A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 9, 2008, Pages 1036-1040

  Hlivko, Jonathan T ^a   Shiffman, Mitchell L ^a   Stravitz, R Todd ^a   Luketic, Velimir A ^a   Sanyal, Arun J ^a   Fuchs, Michael ^a   Sterling, Richard K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 50649118076     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.04.006     Document Type: Article

References (36)

1. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 354 (2006) 54-66
2. Czaja A.J., Bianchi F.B., Carpenter H.A., et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 41 (2005) 207-215
3. Feld J.J., Dinh H., Arenovich T., et al. Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcomes. Hepatology 42 (2005) 53-62
4. Czaja A.J., and Carpenter H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105 (1993) 1824
5. Frazer I.H., Mackay I.R., Bell J., et al. The cellular infiltrate in the liver in auto-immune chronic active hepatitis: analysis with monoclonal antibodies. Liver 5 (1985) 162
6. Krawitt E.L., Kilby A.E., and Albertini R.J. Immunogenetic studies of autoimmune hepatitis: HLA, immunoglobulin allotypes, and autoantibodies. Hepatology 7 (1987) 1305-1310
7. Galbraith R.M., Smith M., Mackenzie R.M., et al. High prevalence of seroimmunological markers in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 290 (1974) 6339
8. Czaja A.J. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4 (1984) 1-12
9. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929
10. Cook G.C., Mulligan R., and Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40 (1971) 159
11. Soloway R.D., Summerskill W.H., Baggenstoss A.H., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63 (1972) 820
12. Murray-Lyon I.M., Stern R.B., and Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1 (1973) 735
13. Johnson P.J., McFarlane I.G., and Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333 (1995) 958-963
14. Czaja A.J., and Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2002) 479-497
15. Mohamadnejad M., Malekzadeh R., Nasseri-Moghhaddam S., et al. Impact of immunesuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 50 (2005) 547-551
16. Czaja A.J. Autoimmune liver disease. Curr Opin Gastroenterol 22 (2006) 234-240
17. Montano Loza A.J., and Czaja A.J. Current therapy for autoimmune hepatitis. Nature Clinical Practice Gastroenterology and Hepatology 4 (2007) 202-214
18. Allison A.C., and Eugui E.M. Immunosupressive and other effects of mycophenolic acid and an ester produrg, mycophenolate mofetil. Immunol Rev 136 (1993) 5-28
19. Kobashigawa J.M.L., Renlund D., Mentzer R., et al. A randomized active controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507-515
20. Warrens A.N. The evolving role of mycophenolate mofetil in renal transplantation. QJM 93 (2000) 15-20
21. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60 (1995) 225-232
22. Eckhoff D.E., McGuire B.M., Frenette L.R., et al. Tacrolimus and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 65 (1998) 180-187
23. Ferraris J.R., Tambutti M.L., Redal M.A., et al. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 70 (2000) 297-301
24. Woodroffe R., Yao G., Meads C., et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 9 (2005) 1-194
25. Richardson P.D., James P.D., and Ryder S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 33 (2000) 371-375
26. Devlin S.M., Swain M.G., Urbanski S.J., et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 18 (2004) 321-325
27. Chatur N., Ramji A., Bain V.G., et al. Transplant immunosupressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 25 (2005) 723-727
28. Inductivo-Yu I., Adams A., Gish R.G., et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 5 (2007) 799-802
29. Czaja A.J., and Carpenter H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 39 (2005) 819-825
30. Czaja A.J., Wolf A.M., and Baggenstoss A.H. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 80 (1981) 687
31. Heneghan M.A., and McFarlane I.G. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35 (2002) 7
32. Dooley M.A., Cosio F.G., Nachman P.H., et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10 (1999) 833-839
33. Karim M., Alba P., Cuadrado M., et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41 (2002) 876-882
34. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 11 Suppl 8 (1993) S117-S119
35. Nowack R., Gobel U., Klooker P., et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10 (1999) 1965-1971
36. Zimmer-Molsberger B., Knauf W., and Thiel E. Mycophenolate mofetil for severe autoimmune hemolytic anemia. Lancet 350 (1997) 1003-1004